Background: The cellular transport proteins ABCB1, ABCC1 and ABCG2 have been implicated in the efflux of some antiretroviral drugs, thus decreasing their intracellular concentrations. Decreased drug accumulation in lymphocytes may allow viral replication and the subsequent emergence of viral resistance leading to treatment failure. Expression of HIV co-receptors on the surface of lymphocytes may influence viral tropism and therefore viral pathogenicity and disease progression. Here, we describe the relationship between expression of transport proteins and chemokine receptors in lymphocytes isolated from HIV-infected individuals and also investigate their relationship with demographic, therapeutic and virological factors.
Introduction
ABCB1 (P-glycoprotein), ABCC1 (multidrug resistance associated protein) and ABCG2 (breast cancer resistance protein) are all members of the ATP-binding cassette transporter superfamily and each protein has been implicated in the transport of one or more antiretroviral compounds. 1 These transporters are expressed in many tissues including lymphocytes, and their activity may serve to lower intracellular accumulation of compounds, including the HIV protease inhibitors (PIs) 2 at their site of action. This creates a sanctuary site for viral replication, thus accelerating the emergence of resistant virus and decreasing efficacy. Expression of ABCB1 has been reported to be influenced by several factors including polymorphisms within the ABCB1 gene (the frequency of which may differ between ethnic groups), 3 gender 4 and various external stimuli. However, relatively few studies have sought to determine demographic predictors of expression of other transport proteins.
The chemokine receptors CXCR4 and CCR5 act as co-receptors for HIV entry into CD4þ cells and their expression has been linked to susceptibility to HIV infection and disease progression following infection. CCR5 is preferentially utilized by HIV in early infection. However, a switch to CXCR4 usage has been temporally linked to rapid CD4þ cell decline and onset of AIDS. 5 Expression of these co-receptors is highly variable and may be affected by numerous factors including genetic polymorphisms, 6 gender 7 and HIV treatment status. 8 We have previously observed a correlation between ABCB1 and CXCR4 expression on peripheral blood mononuclear cells (PBMCs) Fax: þ44-151-7945656; E-mail: rjchand@liv.ac.uk isolated from healthy individuals. 9 No such correlation has yet been reported in HIV-positive individuals, although there is evidence to suggest that expression of both transport proteins 1 and chemokine receptors 8 may be influenced by HIV infection (both directly and indirectly via immune modulation) and by constituents of antiretroviral therapy. It is therefore important to determine whether the relationship persists in PBMC isolated from these patients, in which the activity of transporters and the availability of HIV co-receptors for viral entry play an important role in viral pathogenesis and treatment. Further, as a role for both ABCC1 and ABCG2 has been suggested in the transport of antiretroviral drugs, relationships between expression of these proteins and chemokine receptors may also be of interest.
In this study, we investigated the expression of ABCB1, ABCC1 and ABCG2 as well as the HIV co-receptors CXCR4 and CCR5 in a cross-sectional cohort of HIV-positive patients with differing demographic, virological and treatment backgrounds.
Patients, materials and methods

Patient details
Patients were recruited from the Royal Liverpool University Hospital. Each participant gave informed, written consent and the study was approved by the local research Ethics Committee.
Materials
CXCR4-and CCR5-specific antibodies were provided by the AIDS Reagent Project of the National Institute of Biological Standards and Controls (South Mimms, UK). IgG2a negative control and goat anti-mouse IgG2a:RPE were obtained from Serotech Ltd (Oxford, UK). UIC2 antibody was purchased from Immunotech (Marseilles, France). ABCC1-specific antibody QCRL1 was purchased from Calbiochem (Nottingham, UK) and FITC-conjugated anti-CD4 and Hanks' balanced salt solution were supplied by Sigma Chemical Co. Ltd (Poole, UK). CellFIX was purchased from Becton Dickinson (Oxford, UK). Methanol was obtained from Fisher Scientific (Loughborough, UK) and Ficoll was obtained from Amersham Biosciences (Bucks, UK).
Methods
PBMC were isolated from whole blood (20 mL) obtained from each patient (n ¼ 98) by density gradient centrifugation over Ficoll-Hypaque and stained for expression of ABCB1, ABCC1, ABCG2, CXCR4 and CCR5 as previously described 9,10 using rPE-labelled antibodies. Cells were co-stained for ABCB1 and CXCR4 with CD4 using an FITC-conjugated antibody, and CD4þ and CD42 populations were gated by their positions on the FL1 fluorescence scale following compensation for spectral overlap.
For total PBMC and CD4þ populations, FL2 (rPE) fluorescence was plotted against the number of events and the data registered on a logarithmic scale prior to calculation of the median fluorescence. Surface expression in each population was then determined by subtracting the median fluorescence of isotype control antibody from that of test antibody. Expression data are presented in relative fluorescence units (RFU; arbitrary units) for each protein.
Statistical analysis
All data were tested for normality using the Shapiro-Wilk test. Categorical data were analysed by Mann-Whitney U-test and continuous data by Spearman's rank correlation. Data with a P , 0.1 by univariate analysis was log transformed and tested for significance by multiple linear regression using best subset selection (StatsDirect).
Results
Of the HIV-positive participants (n ¼ 98; 67 male, 31 female), 34 had undetectable viral load (,50 copies/mL), those with detectable viral load had a median of 3.69 log copies/mL (range 1.75 -5.81 log) and the cohort had a median CD4 count of 347 cells/mm 3 (range 8 -1318). Patients were on a range of antiretroviral regimens, with 17 on a PI-containing and 42 a non-PIcontaining regimen. Thirty-nine patients were treatment naive. Of the patients included in the ethnicity analysis, 72 were Caucasian and 19 Black African.
Expression of ABCB1 on CD4þ cells correlated with that measured on total PBMC (r ¼ 0.45, P ¼ 0.0001, n ¼ 69) as did CXCR4 (r ¼ 0.41, P ¼ 0.0007, n ¼ 67). Univariate and multivariate analyses of expression data in PBMC are presented in Table 1 and Figure 1 . Univariate analysis showed a gender effect on ABCB1 expression (mean expression in males 1.02 + 0.45, n ¼ 62, compared with 0.76 + 0.42 RFU in females, n ¼ 30, P ¼ 0.001; Figure 1a) . Expression of ABCB1 correlated with expression of ABCC1 (r ¼ 0.25, P ¼ 0.02, n ¼ 89; Figure 1b) , ABCG2 (r ¼ 0.24, P ¼ 0.03, n ¼ 78, Figure 1c) and CXCR4 (r ¼ 0.54, P , 0.0001, n ¼ 90; Figure 1d ). Multivariate analysis showed gender (P ¼ 0.02) and expression of ABCG2 (P ¼ 0.005) and CXCR4 (P ¼ 0.01) to be independent predictors of ABCB1 expression (Table 1) .
There was a gender effect on ABCC1 (mean expression in males 0.44 + 0.52 RFU, n ¼ 59, compared with 0.24 + 0.3 in females, n ¼ 29, P ¼ 0.02; Figure 1e ), ABCC1 expression correlated with ABCB1 expression (see above) and CXCR4 expression (r ¼ 0.26, P ¼ 0.01, n ¼ 86; Figure 1f ) . However, none of these variables were independent predictors of ABCC1 expression in multivariate analysis.
ABCG2 expression correlated with ABCB1 expression (see above). There was a significant gender effect on CXCR4 expression (mean expression in males 0.47 + 0.22 RFU, n ¼ 62, compared with 0.38 + 0.22 in females, n ¼ 30, P ¼ 0.04; Figure 1g ) and a correlation with ABCB1 and ABCC1 expression (see above). ABCB1 expression was an independent predictor of CXCR4 expression following multivariate analysis (P ¼ 0.01).
Discussion
We have previously demonstrated a positive correlation between expression of ABCB1 and CXCR4 on PBMC isolated from healthy volunteers and have also shown that these two proteins are co-localized within the cell membrane. 9 In this study, we have confirmed these findings in PBMC isolated from HIV-positive individuals. We also found ABCB1 expression to correlate with ABCG2. This raises the possibility that the emergence of CXCR4-tropic strains of HIV, observed in patients with high lymphocyte CXCR4 expression, 11 may be exacerbated by decreased antiretroviral efficacy as a consequence of concomitantly high transporter expression. These strains have been shown to be more lytic to CD4þ cells in vitro.
12
The pharmacokinetics of some HIV drugs (e.g. saquinavir) has been found to vary according to gender with higher exposure seen in women. 13 It is unclear what mechanism is responsible for this difference or whether there is an impact on response to therapy. We found gender to be associated with the expression of ABCB1, with males having higher expression than females; similar correlations were not observed for other transporters by multivariate analysis. Taken together with previous reports of hepatic ABCB1 expression being higher in males than females, 14 it could be argued that our finding of decreased ABCB1 expression in PBMC from female subjects is an indicator of altered expression in other tissues which may in part explain the higher drug exposure of saquinavir 13 and indinavir 15 in females. However, it is important to note that the pharmacokinetics of PIs is driven by first-pass metabolism by cytochrome P450 enzymes as well as drug transporters in the gut and liver, and it is currently unknown whether transporter expression on the PBMC is a valid surrogate for transporters at these sites. Paine et al. 16 have reported no difference in ABCB1 expression in the proximal small intestine between healthy male and female subjects, although hepatic expression has been reported to be higher in males than in females.
14 However, there are no data available regarding HIV-positive patients.
We have previously reported that ex vivo lymphocyte ABCB1 expression inversely correlates with the in vitro antiviral EC 50 of saquinavir 9 and it is possible that any gender-related differences in expression at the lymphocyte may be an additional consideration over and above any gender effects on first-pass metabolism. Studies as to whether treatment outcome varies between genders are equivocal with some studies observing a higher proportion of women than men achieving viral suppression following highly active antiretroviral therapy 17, 18 and others finding no difference in virological or immunological success between the genders. 19, 20 In summary, we present data confirming that the ABCB1/ CXCR4 correlation observed in PBMC isolated from healthy volunteers is also present in cells isolated from HIV-positive individuals. Expression of ABCB1 is also influenced by gender in HIV-positive individuals.
